{"id":22814,"date":"2025-01-24T20:33:58","date_gmt":"2025-01-24T12:33:58","guid":{"rendered":"https:\/\/flcube.com\/?p=22814"},"modified":"2025-01-24T20:34:01","modified_gmt":"2025-01-24T12:34:01","slug":"hengruis-long-acting-insulin-analogue-accepted-for-review-by-chinas-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22814","title":{"rendered":"Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA"},"content":{"rendered":"\n

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276<\/a>) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China’s first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.<\/p>\n\n\n\n

Product Highlights and Market Position<\/strong>
Hengrui’s long-acting insulin analogue is described as having several key advantages, including stable onset, extended duration of drug efficacy, and a low risk of nocturnal hypoglycemia. These features position the product as a competitive alternative to existing treatments in the global market. Similar products currently available include Novo Nordisk’s Tresiba (insulin degludec) and Sanofi’s Toujeo (insulin glargine), both of which have established market presence.<\/p>\n\n\n\n

Implications for Diabetes Treatment in China<\/strong>
The acceptance of Hengrui’s market filing by the NMPA highlights the growing capabilities of China’s domestic pharmaceutical industry in developing innovative biologic products. With type 2 diabetes representing a significant health challenge in China, Hengrui’s long-acting insulin analogue could offer a new treatment option for millions of patients. The company’s efforts underscore its commitment to advancing diabetes care and improving patient outcomes through innovative therapies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for…<\/p>\n","protected":false},"author":1,"featured_media":22815,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,2586,38,852],"class_list":["post-22814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hengrui-pharmaceuticals","tag-market-approval-filings","tag-sha-600276"],"yoast_head":"\nHengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22814\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA\" \/>\n<meta property=\"og:description\" content=\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22814\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T12:33:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T12:34:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"510\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA\",\"datePublished\":\"2025-01-24T12:33:58+00:00\",\"dateModified\":\"2025-01-24T12:34:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814\"},\"wordCount\":224,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2410-png.avif\",\"keywords\":[\"Diabetes\",\"Hengrui Pharmaceuticals\",\"Market approval filings\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22814#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22814\",\"name\":\"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2410-png.avif\",\"datePublished\":\"2025-01-24T12:33:58+00:00\",\"dateModified\":\"2025-01-24T12:34:01+00:00\",\"description\":\"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22814\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2410-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2410-png.avif\",\"width\":1080,\"height\":510,\"caption\":\"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22814#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA - Insight, China's Pharmaceutical Industry","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22814","og_locale":"en_US","og_type":"article","og_title":"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA","og_description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.","og_url":"https:\/\/flcube.com\/?p=22814","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-24T12:33:58+00:00","article_modified_time":"2025-01-24T12:34:01+00:00","og_image":[{"width":1080,"height":510,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22814#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22814"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA","datePublished":"2025-01-24T12:33:58+00:00","dateModified":"2025-01-24T12:34:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22814"},"wordCount":224,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22814#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","keywords":["Diabetes","Hengrui Pharmaceuticals","Market approval filings","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22814#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22814","url":"https:\/\/flcube.com\/?p=22814","name":"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22814#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22814#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","datePublished":"2025-01-24T12:33:58+00:00","dateModified":"2025-01-24T12:34:01+00:00","description":"China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China's first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22814#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22814"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22814#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","width":1080,"height":510,"caption":"Hengrui's Long-Acting Insulin Analogue Accepted for Review by China's NMPA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22814#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2410-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22814"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22814\/revisions"}],"predecessor-version":[{"id":22816,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22814\/revisions\/22816"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22815"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}